• International only enterprise to successfully develop absorbable in-vivo surgical hemostatic materials using modified chitosan.
• International only enterprise to achieve technological breakthroughs in in-vivo fully degradable vascular stent development using marine polysaccharides.
• International only manufacturer of chitosan-based Class III military wound treatment products.
• Possesses exclusive medical-grade chitosan production and processing technology.
• 40+ years of founder R&D accumulation with 40+ patented technologies.
Qingdao Biotemed Biomaterials Co., Ltd. is a leading contributor to the development and revision of China's industry standards, including YY/T 1699-2020 Tissue Engineering Medical Devices — Chitosan and YY/T 0953-2020 Medical Carboxymethyl Chitosan.The company operates GMP-certified manufacturing facilities designed to meet the production requirements for EU Class III medical devices, featuring ISO Class 8 cleanroom environments with localized ISO Class 5 critical production areas.As a key technology-driven enterprise in the marine biopharmaceutical sector, Biotemed is committed to advancing innovative biomaterial solutions for global healthcare applications.

Biotemed has consistently undertaken national R&D programs from the 11th to 14th Five-Year Plans in chitosan material innovation, holding over 30 authorized national and international invention patents. The company has received numerous awards including the National Science and Technology Progress Award (Second Class), Shandong Provincial Ocean Science and Technology Award (First Class), and Shanghai Municipal Science and Technology Award (First Class). It is recognized as a Ministry of Science and Technology industry-academia-research demonstration unit, a national marine biomaterials engineering technology joint innovation research base, and a post-doctoral research station.

International only enterprise to successfully develop absorbable in-vivo surgical hemostatic materials using modified chitosan, with technology reaching international leading levels and granted domestic and international patent authorization.
International only enterprise to conduct in-vivo fully degradable vascular stent development using marine polysaccharides and achieve technological breakthroughs.
International only manufacturer of chitosan-based Class III military wound treatment products.
Possesses exclusive medical-grade chitosan and medical-grade modified chitosan production and processing technology with high technical barriers that are difficult for other enterprises to imitate.
Founder's 40+ years of R&D accumulation, with over 40 patented technologies providing a foundation for future broad material transformation.













































